Pharvaris is a clinical stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients.
Pharvaris has raised €67M across 1 funding round from 2 investors, most recently a Series C round in Nov 2020. Based in Zug, Switzerland; founded 2015; active in Healthtech. The company has exited (2025). Data as of 7 Aug 2026.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-11-18 | Series C | €67M | General Atlantic,Viking Global Investors | View deal → |
